DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20175429

Antifungal susceptibilities and identification of Candida species by using maldi-tof microbial identification system from cervicovaginal samples

Göksel Erbaş, Uğur Parin, Şükrü Kirkan, Süheyla Türkyilmaz, Serap Savaşan, Hafize Tuğba Yüksel, Sinem Öztürk

Abstract


Background: Among the vaginal diseases seen in women, candidiasis is in the first place. This disease, which is caused by Candida species, can sometimes persist very stubbornly. The aim of this study was to determine Candida species isolated from vaginal specimens by using VITEK MS (MALDI-TOF Microbial Identification System) rapid identification system and to evaluate their susceptibility to some antifungals.

Methods: In this study, 220 cervicovaginal swab were used. Isolates were identified by VITEK MS rapid identification system. After identification, antifungal susceptibility testing was performed using the M-44 A2 guideline of The Clinical and Laboratory Standards Institute (CLSI).

Results: Total 16.3% (36) of Candida spp. positivity was determined from 220 cervicovaginal samples, and 25 (69.4%) C. glabrata, 6 (16.7%) C. albicans, 3 (8.3%) C. kefyr and 2 (5.6%) C. krusei were obtained with Vitek MS. All identified C. albicans strains were found to be completely resistant to all antifungals used except nystatin agent, C. krusei strains were found to be resistant to flucytosine but sensitive to all other antifungals, C. glabrata and C. kefyr strains were susceptible to all antifungals within the antifungals used in this study.

Conclusions: It is concluded that it is necessary to distinguish Candida species in order to apply a correct treatment. And species selection is very important for the selection of antifungal to be used. Nystatin is recommended if no laboratory tests are to be performed for the diagnosis of Vaginal Candidiasis.


Keywords


Antifungal, Candida, Vaginal Candidiasis, Vitek MS

Full Text:

PDF

References


Holland J, Young ML, Lee O, C-A Chen S. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect. 2003;79(3):249-50.

Rangaraj S, Uyen B, Ajit PL, Cookson BT. Rapid identification of commonly encountered Candida species directly from blood culture bottles. J Clin Microbial. 2003;41(12):5660-64.

Warnock DW. Trends in the epidemiology of invasive fungal infections. Nihon Ishinkin Gakkai Zasshi. 2007;48(1):10-12.

Holt JG, Krieg NR, Sneath PHA, Staley JT, Williams ST. Bergey’s Manual of Determinative Bacteriology. 9th edn. Baltimore, Md, USA: Wiliams and Wilkins;1994.

Sonmez M, Erbas G. Isolation and Identification of Candida spp. from Mastitis Cattle Milk and Determination of Antifungal Susceptibilities. Inter J Veterinary Sci. 2017;6(2):104-07.

Duran-Valle MT, Sanz-Rodriguez N, Munoz-Paraiso C, Almagro- Molto M, Gomez-Garces JL. Identification of clinical yeasts by Vitek MS system compared with API ID 32 C. Med Mycol. 2014;52:342-49.

Clinical Laboratory Standards Institute (CLSI). Method for Antifungal disk diffusion Susceptibility testing of Yeasts: Approved Guidelines, second edition. CLSI document M44-A2 (ISBN 1-56238-703-0). Clinical Laboratory Standard Institute, Wayne: Pennsylvania;2009.

Shokohi T, Soteh MB H, Pouri ZS, Hedayati MT, Mayahi S. Identification of Candida species using PCR-RFLP in cancer patients in Iran. Ind J Medic Microbiol. 2009;28:147-51.

Colombo AL, Guimarães T, Camargo LF, Richtmann R, de Queiroz-Telles F, Salles MJ, et al. Brazilian guidelines for the management of candidiasis–a joint meeting report of three medical societies: Sociedade Brasileira de Infectologia, Sociedade Paulista de Infectologia and Sociedade Brasileira de Medicina Tropical. Braz J Infec Dis. 2013;17(3):283-312.

Beikert FC, Le MT, Koeninger A, Technau K, Clad A. Recurrent vulvovaginal candidosis: focus on the vulva. Mycoses. 2011;54:807-10.

Oriel JD, Partidge BM, Denny MJ, Coleman JC. Genital infections. Br Med J. 1972;4:761-64.

Consolaro ME, Albertoni TA, Yoshida CS, Mazucheli J, Peralta RM, Svidzinski TI. Correlation of Candida species and symptoms among patients with vulvovaginal candidiasis in Maringá, Paraná, Brazil. Rev Iberoam Micol. 2004;21(4):202-5.

Spinillo A, Capuzzo E, Egbe TD, Baltaro F, Nicola S, Piazzi G. Torulopsis glabrata vaginitis. Obstet Gynecol. 1995;85:993-98.

Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000–2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses. 2006;49:471-75.

Ozcan SK, Budak F, Yucesoy G, Susever S, Willke A. Prevalence, susceptibility profile and proteinase production of yeasts causing vulvovaginitis in Turkish women. APMIS. 2006;114:139-45.

Vermitsky JP, Self MJ, Chadwick SG, Trama JP, Adelson ME, Mordechai E, et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clinic Micro. 2008;46(4):1501-3.

Okungbowa FI, Isikhuemen O, Dede APO. The distribution frequency of Candida species in the genitourinary tract among symptomatic individuals in Nigerian cities. Revista iberoamericana de micología. 2003;20(2):60-63.

St-Germain G, Laverdiere M, Pelletier R, Bourgault AM, Libman M, Lemieux C, Noel G. Prevalence and Antifungal Susceptibility of 442Candida Isolates from Blood and Other Normally Sterile Sites: Results of a 2-Year (1996 to 1998) Multicenter Surveillance Study in Quebec, Canada. J Clinic Microbiol. 2001;39(3):949-53.

Dias LB, Melhem MSC, Szeszs MW, Filho JM, Hahn RC. Vulvovaginal candidiasis in Mato Grosso, Brazil: pregnancy status, causative species and drugs tests. Braz J Microbiol. 2011;42:1300-07.

Aquino VR, Lunardi LW, Goldani LZ, Barth AL. Prevalence, susceptibility profile for fluconazole and risk factors for candidemia in a tertiary care hospital in southern Brazil. Braz J Infect Dis. 2005;9(5):411-18.

Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43:2155-62.

Fan SR, Lui XP. In vitro fluconazole and nystatin susceptibility and clinical outcome in complicated vulvovaginal candidosis. Mycoses. 2010;54:501-05.